Navigation Links
Selexis Launches Biosimilar Cell Line Development Program
Date:3/30/2009

As the world leader of cell line manufacturing, Selexis is now offering a portfolio of cell lines expressing biosimilar recombinant protein drugs with added characterization services

GENEVA, March 31 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company offering technologies and services for the rapid development of high-performance stable production cell lines announced today an expanded offering focusing on the biosimilar market segment. Under the new program, Selexis will offer clients the contract development of high producing mammalian cell lines expressing biosimilars, including expanded characterization capabilities. Selexis scientists have already demonstrated, using the Selexis SURE Cell Line Development(SM) Platform, the production of biosimilars proteins at levels as much as 50 fold greater than the currently marketed drugs. The Selexis' SURE Cell Line Development(SM) platform combines Selexis' Intellectual Property rights (e.g. novel genetic elements DNA sequences and transfection procedures) with its cell culture know-how for the rapid development of biosimilars products.

Dr. Igor Fisch, President and CEO of Selexis, commented:

"We feel it is a very important step towards the creation of a global company offering fully integrated services to our client worldwide by including biosimilar expressing cell lines Importantly, in support of this new offer, we are also expanding our support of product characterization capabilities which will further enhance the value of this package".

By combining proprietary technologies with know-how on a fully integrated platform, Selexis can provide top performance cell lines in a industry-known and accepted package.

About Biosimilars:

Biosimilars or Follow-on biologics are terms used to describe officially approved new versions of innovator biopharmaceutical products, following patent expiry.

Ab
'/>"/>

SOURCE Selexis
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. First Application to Fight High Cholesterol Launches on the iPhone and iPod Touch
2. Merck Serono Launches Strategic Venture Capital Fund
3. Boston Scientific Launches New Coronary Imaging Catheter
4. LUMEDX Launches New Interventional Radiology Software
5. Venter Institute Launches the J. Robert Beyster and Life Technologies 2009-2010 Research Voyage of the Sorcerer II Expedition
6. StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies
7. PDHI Launches Short Form of Its ConXus Profile Health Assessment
8. Zymes Omega Solutions Bottles and Launches the Worlds First Omega-3 Enhanced Water
9. Irvine Scientific Launches IS CHO-CD XP(TM)
10. Pyratine XR(TM) Launches at 67th AAD Meeting, Offering Hope to 14 Million Rosacea Sufferers
11. Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)... The Human Anthrax Vaccine Program must be sto...feature film "A Call to Arms:2009 Edition&quo...atal Immunity: The Human Anthrax Vaccine Story&quo...t danger of top secret government science turned i...untability to its victims. It is available for wo...
(Date:11/4/2009)..., Nov. 4 Star Scientif...he company plans to introduce the CigRx(TM) nutrac...Creek Pharmaceuticals, for worldwide marketing and... . (Nasdaq: VTIV). inVentiv Health offers a compl... stage of the product lifecycle, in a range of hea...
(Date:11/4/2009)...if., Nov. 4 Onyx Pharmac...at it will present at the Credit Suisse 18th Annua... at 9:30 a.m. Mountain Time (8:30 a.m. Pacific Tim...of the presentation on our website at: http://ww..., It is recommended that listeners log on 15 minut...
(Date:11/4/2009)...STOWN, Pa., Nov. 4 Emerson Resou...ompany, today announced that it has formed a strat... research organization that specializes in the agr...d its business development capabilities. The exclu...ry veteran Robert Westbrook, CEO of Bio Research, ...
Breaking Biology Technology:Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 2Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 3Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health 4Emerson Resources Forges Strategic Partnership with Bio Research 2
...liminate animal testing in the chemicals and cosme...n the development of new pharmaceuticals, accordin...nsselaer Polytechnic Institute, the University of ...c. , The team,s most recent discovery will be fe...ngs of the National Academy of Sciences (PNAS) on ...
...tage Molecule for the Treatment..., Alberta, Dec. 17 ,Eli Lilly and Company (NYSE: ...unced that the two companies have entered into a l...exclusive worldwide rights to BioMS,Medical,s lead...mpound is,currently being evaluated in two pivotal...
...PharmaTech Inc. (TSX,Venture Exchange: QPT) today ...ultinational technology development company (the "...gy products based on its SonoLight Technology.,Und...nc. ("Quest" or the,"Company") has already receive...e paid within the next twelve months. In return fo...
Other Biology Technology:Biochip mimics the body to reveal toxicity of industrial compounds 2Biochip mimics the body to reveal toxicity of industrial compounds 3Lilly and BioMS Medical Announce Global Licensing and Development Agreement 2Lilly and BioMS Medical Announce Global Licensing and Development Agreement 3Lilly and BioMS Medical Announce Global Licensing and Development Agreement 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 5Lilly and BioMS Medical Announce Global Licensing and Development Agreement 6Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology 2
(Date:11/3/2009)...ed in a recent issue of HortTechnology , scientis...ects of covering orchard floors with reflective fi...stribution, orchard temperature, and profitability...d Solarmate films installed 5 weeks before commerc...The research showed that the use of both films inc...
(Date:11/3/2009)...as 28 percent less likely to become pregnant and h...that earned a Michigan State University professor ..., a researcher in the MSU College of Human Medicin...ductive Biology, focused on data of nearly 50,000 ...Luke,s findings, which also can be applied to wome...
(Date:11/3/2009)...l of Engineering and Applied Science have for the ...atory the enzyme responsible for producing the blo..., The research, published Oct. 23 in the journal...ent of other compounds with similarly beneficial e...is one of the most interesting but least understoo...
Breaking Biology News(10 mins):Reflective film can boost profits for apple growers 2MSU researcher: Obesity significantly cuts odds of successful pregnancy 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2Halloween sex offender policies questioned 59957 1Halloween sex offender policies questioned 59957 2RIT scientist shines laser light on methane in pursuit of clean fuel 10490 1RIT scientist shines laser light on methane in pursuit of clean fuel 10490 2Scientists create NICE solution to pneumonia vaccine testing problems 10488 1Scientists create NICE solution to pneumonia vaccine testing problems 10488 2
...once credited with magical healing powers but are ...oses but the cause of numerous diseases such as di...gests this view ignores the vital role played by m...and the great therapeutic potential they have. , ...y the European Science Foundation (ESF) on the cur...
...n. 16, 2008) -- The National Heart, Lung, and Bloo...n grant to the Center of Vascular Biology at Weill...edical research into vascular disease -- specifica...r risk factors for coronary artery disease, heart ...arded to Drs. Katherine and David Hajjar represent...
...uary 16, 2008) The latest medications can delay t... to reverse its devastating effects. This limitati...rs patients maintaining a good quality of life for...ped by the Georgia Institute of Technology and Emo...inexpensive test that could be administered as par...
Other Biology News:ESF's workshop restores good name of sugar 2ESF's workshop restores good name of sugar 3$13 million federal grant for research into vascular disease awarded to Weill Cornell 2Portable device quickly detects early Alzheimer's 2Portable device quickly detects early Alzheimer's 3
...k system! Program your valve and TTL on-off seque...XP using graphic 'click-and-drag' timebars. Save a...ram listings, then download your programs into the...Code is used for programming before -- not during ...
Mouse Anti-Tubulin IV, beta Monoclonal Antibody, Unconjugated, Clone ONS.1A6 from Sigma-Aldrich
Mouse Anti-Sulfadimethoxine Monoclonal Antibody, Unconjugated, Clone CH-2027 from Santa Cruz Biotechnology, Inc.
... MAP1A and MAP1B are microtubule-associated protei... microtubules and components of the cytoskeleton. ...nit and multiple light chain subunits. The protein...bunits and can associate with either MAP1A or MAP1...
Biology Products: